ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CTNM Contineum Therapeutics Inc

15.975
-0.025 (-0.16%)
Last Updated: 15:04:28
Delayed by 15 minutes

Period:

Draw Mode:

Volume 130,319
Bid Price 15.95
Ask Price 16.15
News -
Day High 16.33

Low
13.27

52 Week Range

High
18.50

Day Low 14.69
Company Name Stock Ticker Symbol Market Type
Contineum Therapeutics Inc CTNM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.025 -0.16% 15.975 15:04:28
Open Price Low Price High Price Close Price Prev Close
15.53 14.69 16.33 16.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
940 130,319 $ 15.92 $ 2,074,316 - 13.27 - 18.50
Last Trade Time Type Quantity Stock Price Currency
15:04:28 100 $ 15.975 USD

Contineum Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
410.8M 25.72M - 50M 22.72M 0.88 18.08
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Contineum Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CTNM Message Board. Create One! See More Posts on CTNM Message Board See More Message Board Posts

Historical CTNM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.0318.0314.6916.1338,853-2.06-11.40%
1 Month15.8318.5014.6016.1040,5650.1450.92%
3 Months14.5018.5013.2715.5474,3511.4810.17%
6 Months14.5018.5013.2715.5474,3511.4810.17%
1 Year14.5018.5013.2715.5474,3511.4810.17%
3 Years14.5018.5013.2715.5474,3511.4810.17%
5 Years14.5018.5013.2715.5474,3511.4810.17%

Contineum Therapeutics Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Your Recent History

Delayed Upgrade Clock